NK cells and NKT cells in innate defense against viral infections

Current Opinion in Immunology

Volumn 13, Issue 4, 2001, Pages 458-464

  Biron, C A ^a   Brossay, L ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIVIRUS AGENT; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR;

ARTICLE; CELL ACTIVATION; CELL POPULATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMMUNOREGULATION; INFECTION PREVENTION; INTERFERON PRODUCTION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROMOTER REGION; SIGNAL TRANSDUCTION; TARGET CELL; VIRUS INFECTION;

EID: 0035424543     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00241-7     Document Type: Review

References (53)

1. Natural killer cells in antiviral defense: Function and regulation by innate cytokines
2. NK cell receptors
3. Mouse CD1-specific NK1 T-cells: Development, specificity, and function
4. The CD1 system: Antigen-presenting molecules for T-cell recognition of lipids and glycolipids
5. CD1d-restricted and TCR-mediated activation of Vα14 NKT-cells by glycosylceramides
6. CD1d-mediated recognition of an α-galactosyl-ceramide by natural killer T-cells is highly conserved through mammalian evolution
7. Murine CD1d-restricted T-cell recognition of cellular lipids
8. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T-cells
9. Innate immunity and viral infections
10. The biology of chemokines and their receptors
11. Human natural killer cells produce abundant macrophage inflammatory protein-1 α in response to monocyte-derived cytokines
12. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro
13. + patients produce C-C chemokines and inhibit HIV-1 infection
14. Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection
15. Two roads diverged: Interferon α/β- and interleukin 12-mediated pathways in promoting T-cell interferon γ responses during viral infection
16. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
17. Interferon β in multiple sclerosis: Is IL-12 suppression the key?
18. Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection
19. Interferon α/β-mediated inhibition and promotion of interferon γ: STAT1 resolves a paradox
20. Regulation of the natural killer cell receptor repertoire
21. On guard- activating NK cell receptors
22. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
23. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)
24. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
25. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40
26. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype
27. Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1
28. Vital involvement of a natural killer cell activation receptor in resistance to viral infection
29. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily
30. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors
31. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo
32. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
33. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells
34. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration
35. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense
36. Selective IL-18 requirements for induction of compartmental IFN-γ responses during viral infection
37. Compartmental differences in NK cell responsiveness to IL-12 during lymphocytic choriomeningitis virus infection
38. Perforin gene defects in familial hemophagocytic lymphohistiocytosis
39. Nitric oxide and macrophage function
40. Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus
41. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways
42. + cells and murine cytomegalovirus infection: What happens in situ?
43. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection
44. In vivo identification of glycolipid antigen-specific T-cells using fluorescent CD1d tetramers
45. Tracking the response of natural killer T-cells to a glycolipid antigen using CD1d tetramers
46. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography
47. Immunization with α-galactosylceramide polarizes CD1-reactive NK T-cells towards Th2 cytokine synthesis
48. Cross-talk between cells of the innate immune system: NKT-cells rapidly activate NK cells
49. Selective induction of NK cell proliferation and cytotoxicity by activated NKT-cells
50. Natural killer T-cell activation inhibits hepatitis B virus replication in vivo
51. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus
52. Rapid death and regeneration of NKT-cells in anti-CD3- or IL-12-treated mice: A major role for bone marrow in NK T-cell homeostasis
53. Activation of hepatic NKT-cells and subsequent liver injury following administration of α-galactosylceramide